Author + information
- David Bobrowski,
- Limei Zhou,
- Peter Austin,
- Oscar Calvillo Arguelles,
- Eitan Amir,
- Douglas Lee,
- Paaladinesh Thavendiranathan and
- Husam Abdel-Qadir
Limited data suggest that statins may protect against cardiotoxicity after chemotherapy with anthracyclines and trastuzumab.
Using linked administrative databases, we conducted a population-based retrospective cohort study of women aged ≥66 years diagnosed with early stage breast cancer (EBC) in Ontario from 2007-2017. We studied women who received anthracyclines or trastuzumab in the year after diagnosis as separate cohorts. Propensity scores (PS) were used to match statin-treated with unexposed women (1:1) in each cohort; trastuzumab-treated women were also matched on prior anthracycline use. We used cumulative incidence functions to describe the risk of hospitalization or emergency department (ED) visits (hospital visits) for heart failure (HF) and cause-specific regression to quantify the relative rate of HF.
From 2545 anthracycline-treated women and 1345 trastuzumab-treated women, we matched 723 statin-discordant pairs of anthracycline-treated women (median age 69 years) and 399 pairs of trastuzumab-treated patients (median age 71 years). The risk of HF hospital visits in both cohorts was significantly lower with statin exposure (see figure); the cause-specific hazard ratio was 0.42 (95% CI 0.22-0.82) in the anthracycline cohort and 0.34 (95% CI 0.14-0.82) in the trastuzumab cohort.
Statin exposure is associated with substantially lower rates of HF after anthracycline- and trastuzumab-based chemotherapy for EBC.
Posters Hall_Hall A
Saturday, March 28, 2020, 12:30 p.m.-1:15 p.m.
Session Title: Heart Failure and Cardiomyopathies: Therapy 2
Abstract Category: 14. Heart Failure and Cardiomyopathies: Therapy
Presentation Number: 1157-079
- 2020 American College of Cardiology Foundation